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OBJECTIVES We investigated the effects of a novel ultrapotent poly(adenosine diphosphate-ribose)
polymerase (PARP) inhibitor, PJ34, on cardiac and endothelial dysfunction in a rat model of
chronic heart failure (CHF).
BACKGROUND Overactivation of the nuclear enzyme PARP importantly contributes to the development of
cell dysfunction and tissue injury in various pathophysiologic conditions associated with
oxidative stress, including myocardial reperfusion injury, heart transplantation, stroke, shock,
and diabetes.
METHODS Chronic heart failure was induced in Wistar rats by chronic ligation of the left anterior
descending coronary artery. Left ventricular (LV) function and ex vivo vascular contractility
and relaxation were measured 10 weeks after the surgery. Nitrotyrosine (NT) formation and
PARP activation were detected by immunohistochemistry.
RESULTS Chronic heart failure induced increased NT formation and PARP activation in the
myocardium and intramural vasculature, depressed LV performance, and impaired vascular
relaxation of aortic rings. PJ34 significantly decreased myocardial PARP activation but not
NT formation, and improved both cardiac dysfunction and vascular relaxation.
CONCLUSIONS Poly(ADP-ribose) polymerase inhibition represents a novel approach for the experimental
treatment of CHF. (J Am Coll Cardiol 2002;40:1006–16) © 2002 by the American
College of Cardiology Foundation
Poly(adenosine diphosphate-ribose) polymerase (PARP) is
a nuclear enzyme with multiple regulatory functions. The
PARP cleaves nicotinamide adenine dinucleotide (NAD)
to nicotinamide and ADP-ribose to form long branches
(ADP-ribose) polymers on glutamic acid residues of a
number of target proteins including histones and PARP
(automodification domain) itself. Poly(ADP-ribosyl)ation is
involved in the regulation of many cellular processes such as
deoxyribonucleic acid (DNA) repair, gene transcription, cell
cycle progression, cell death, chromatin function, and
genomic stability. When PARP is overactivated by oxygen-
and nitrogen-derived radical-induced DNA single-strand
breaks, it produces extended chains of ADP-ribose on
nuclear proteins and results in substantial depletion of
intracellular NAD. As NADH functions as an electron
carrier in the mitochondrial respiratory chain, NAD de-
pletion rapidly leads to falling intracellular adenosine
triphosphate levels, eventually leading to cellular dysfunc-
tion and death (1) (Fig. 1). Overactivation of PARP
represents an important novel mechanism of cell dysfunc-
tion in various pathophysiologic conditions associated with
increased oxidative stress, including myocardial reperfusion
injury (2,3), heart transplantation (4), circulatory shock
(5,6), stroke (7), and diabetes mellitus and its complications
(8–11). Oxidative stress plays a pathogenetic role in chronic
heart failure (CHF) (12–17). We investigated whether
pharmacologic inhibition of PARP affects cardiac and
vascular function in a rat model of CHF.
MATERIALS AND METHODS
The investigation conformed to the Guide for the Care and
Use of Laboratory Animals published by the National Insti-
tutes of Health, and was performed with approval of the
local Animal Care and Use Committee.
Surgical preparation. Male Wistar rats (Charles River) (97
animals) weighing 300 to 330 g were anesthetized with
intraperitoneal thiopentone sodium (60 mg/kg). The ani-
mals were intubated under direct vision with polyethylene
tubing and placed on artificial ventilation (75 strokes/min,
tidal volume  8 ml/kg, inspired fraction of oxygen  0.5)
using a Harvard model 683 respirator (Harvard, Holliston,
Massachusetts). A positive end-expiratory pressure of 5 cm
H2O was applied to minimize atelectasis. The animals were
placed on controlled heating pads, and core temperature
measured via rectal probe was maintained at 37°C. The
animals were given an analgesic (buprenorphine 0.25 mg/kg
subcutaneously) before surgery and an identical dose 6 h
later.
Myocardial infarction model. Coronary artery ligation
was performed in 81 animals, as previously described
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(18,19). Following a left thoracotomy at the fourth inter-
costal space under aseptic conditions, the pericardium was
opened and the heart briefly exteriorized. The left anterior
descending (LAD) coronary artery was then permanently
ligated by an intramural 5.0 silk suture, inserted from below
the tip of the left atrial appendage up to the pulmonary
conus. The chest wall was closed in layers using 4.0 silk
suture. Animals were rapidly weaned from the ventilator
and placed in cages with free access to food and water. A
group of 16 rats had the same surgical procedure, except that
the LAD was not occluded (sham group).
Treatment protocol. Twenty-four hours after the coronary
occlusion, the surviving animals were randomly assigned to
receive a daily intraperitoneal injection of an ultrapotent
water-soluble PARP inhibitor, PJ34 (9) (20 mg/kg dis-
solved in 0.5 ml isotonic saline; PJ34 group, n  16), or
isotonic saline (0.5 ml; control group, n 15). The selected
treatment regimen is effective in blocking vascular and
cardiac PARP activation, as confirmed by direct measure-
ment of poly(ADP-ribose) formation (9,11,20). The start of
the PARP inhibitor treatment was delayed by 24 h to avoid
suppression by PARP inhibition of infarct size (18–21).
Abbreviations and Acronyms
CHF  chronic heart failure
DNA  deoxyribonucleic acid
dP/dt  systolic pressure increment
dP/dt  diastolic pressure decrement
iNOS  inducible isoform of nitric oxide synthase
LAD  left anterior descending coronary artery
LV  left ventricle/ventricular
LVSP  left ventricular systolic pressure
LVEDP  left ventricular end-diastolic pressure
NAD  nicotinamide adenine dinucleotide
3-NT  3-nitrotyrosine
PARP  poly(adenosine diphosphate-ribose)
polymerase
PBS  phosphate buffered saline
SNK  Student-Newman-Keuls
Figure 1. Proposed role of poly(adenosine diphosphate-ribose) polymerase (PARP) in oxidant-induced cellular dysfunction and necrosis. Oxygen and
nitrogen-derived radicals cause stand breaks in deoxyribonucleic acid (DNA), activating PARP. Activation of PARP initiates an energy-consuming cycle
by transferring adenosine diphosphate-ribose units from nicotinamide adenine dinucleotide (NAD) to nuclear proteins resulting in rapid depletion of the
intracellular NAD and adenosine triphosphate (ATP) pools, slowing the rate of glycolysis and mitochondrial respiration, eventually leading to cellular
dysfunction and death. ADPR  adenosine diphosphate-ribose; NADH  reduced nicotinamide adenine dinucleotide; ONOO  peroxynitrite.
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The sham rats were also given a daily intraperitoneal
injection of isotonic saline (0.5 ml; n  8) or PJ34 (20
mg/kg; n  8). Treatments continued for 10 weeks.
Measurements. LEFT VENTRICULAR (LV) FUNCTION. At
the end of the 10 weeks of observation, LV function was
determined as described (11,18). Animals were anesthetized
with thiopentone sodium (60 mg/kg intraperitoneally) and
tracheotomized to facilitate breathing. Animals were placed
on controlled heating pads, and core temperature as mea-
sured via a rectal probe was maintained at 37°C. A microtip
catheter transducer (SPR-524, Millar Instruments, Hous-
ton, Texas) was inserted into the right carotid artery and
advanced into the LV under pressure control. After stabi-
lization for 20 min, the pressure signal was continuously
recorded using a MacLab A/D converter (AD Instruments,
Mountain View, California) and stored and displayed on an
Apple Macintosh computer. The heart rate and left ven-
tricular systolic pressure (LVSP) and left ventricular end-
diastolic pressure (LVEDP) were measured and the maxi-
mal slopes of systolic pressure increment (dP/dt) and
diastolic pressure decrement (dP/dt), indexes of contrac-
tility and relaxation, were calculated. After these measure-
ments, the catheter was pulled back into the aorta to
measure of arterial blood pressure.
INFARCT SIZE AND CARDIAC REMODELING. Following the
hemodynamic measurements, animals were killed by exsan-
guination. The heart was removed and the different cavities
(left and right ventricles, left and right atria) were dissected
and weighed. The weight of each cavity was then normal-
ized to the length of the right tibia. The infarcted (scar) area
of the LV was then carefully dissected from the nonin-
farcted LV, and infarct size was evaluated by computing the
ratio of scar tissue weight to the total LV weight. The lungs
were also removed and weighed, and wet lung weights were
normalized to tibia length and were used as an index of
extravascular water lung accumulation.
After these measurements, noninfarcted LVs were fixed
in 10% formalin, sliced, and embedded in paraffin for
immunohistochemical detection of 3-nitrotyrosine (NT)
and poly(ADP-ribose) formation.
IMMUNOHISTOCHEMICAL DETECTION OF NT. Paraffin sec-
tions (3 m) were deparaffinized in xylene and rehydrated in
decreasing concentrations (100%, 95%, and 75%) of ethanol
followed by a 10-min incubation in phosphate buffered
saline (pH 7.4). Sections were treated with 0.3% hydrogen
peroxide for 15 min to block endogenous peroxidase activity
and then rinsed briefly in PBS. Nonspecific binding was
blocked by incubating the slides for 1 h in 0.25% Triton/
PBS containing 2% horse serum. Mouse monoclonal anti-
nitrotyrosine antibody (Upstate Biotechnology, Lake Placid,
New York) and isotype-matched control antibody were
applied in a dilution of 1:200 for 1 h at room temperature.
After extensive washing (3  10 min) with 0.25% Triton/
PBS, immunoreactivity was detected with a biotinylated
horse antimouse secondary antibody and avidin-biotin-
peroxidase complex, both supplied in the Vector Elite kit
(Vector Laboratories, Burlingame, California). Color was
developed using the Ni-DAB substrate kit (Vector Labo-
ratories). Sections were then counterstained with nuclear
fast red, dehydrated, and mounted in Permount. Photomi-
crographs were taken with a Zeiss Axiolab microscope
equipped with a Fuji HC-300C digital camera.
Extent of immunoreactivity in cells was determined by
measuring the optical density of NT signal in the myocytes.
The background intensity was subtracted from the images
and an average optical density of myocytes was determined
for each image as a measure of average staining intensity as
described (22). A total of 18 to 26 images were examined in
each condition from four to five hearts.
IMMUNOHISTOCHEMICAL DETECTION OF POLY(ADP-
RIBOSE). Poly(ADP-ribose) was detected as described (11)
with minor modifications, as follows. Mouse monoclonal
anti-poly(ADP-ribose) antibody (Alexis, San Diego, Cali-
fornia) and isotype-matched control antibody were applied
in a dilution of 1:600 for 1 h at room temperature. After
extensive washing (3  10 min) with 0.25% Triton/PBS,
immunoreactivity was detected with a biotinylated horse
antimouse secondary antibody and avidin-biotin-peroxidase
complex, both supplied in the Vector Elite kit (Vector
Laboratories). Color was developed using the Ni-DAB
substrate kit (Vector Laboratories). Sections were then
counterstained with nuclear fast red, dehydrated, and
mounted in Permount. Photomicrographs were taken with
a Zeiss Axiolab (Charlotte, Vermont) microscope equipped
with a Fuji HC-300C digital camera. All histologic and
immunohistochemical samples were coded and examined
and graded by an investigator in a blinded fashion.
Quantification of the intensity of the poly(ADP-ribose)
staining was performed as previously published (11). The
percentage of PARP-positive nuclei of cardiomyocytes was
obtained by conventional microscopy. A total of 2,532 to
3,452 nuclei profiles were examined in each condition, in at
least six different animals in each group. The results are
expressed as the percent of PARP-positive nuclei of myo-
cytes relative to the number of total nuclei counted.
VASCULAR FUNCTION IN ISOLATED AORTIC RINGS. Tho-
racic aortae were removed and cleared from periadventitial
fat and cut into 3 to 4 mm width rings using an operation
microscope, then mounted in organ baths filled with
warmed (37°C) and oxygenated (95% O2, 5% CO2) Krebs’
solution (CaCl2 1.6 mM; MgSO4 1.17 mM; EDTA 0.026
mM; NaCl 130 mM; NaHCO3 14.9 mM; KCl 4.7 mM;
KH2PO4 1.18 mM; glucose 11 mM). Isometric tension was
measured with isometric transducers (Kent Scientific Cor-
poration, Litchfield, Connecticut), digitized using a MacLab
A/D converter, and stored and displayed on a Macintosh
computer. A tension of 1.5 g was applied and the rings were
equilibrated for 60 min, followed by measurements of the
concentration-dependent contraction to epinephrine (1010 to
3  105 M), and in rings precontracted with epinephrine
(106 M), relaxation to acetylcholine (109 to 3  104 M),
and sodium nitroprusside (1012 to 105 M).
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Reagents. All reagents were obtained from Sigma/Aldrich
(St. Louis, Missouri), unless indicated otherwise. The
potent, novel, water-soluble phenanthridinone derivative
PARP inhibitor, PJ34—the hydrochloride salt of N-(-oxo-
5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacet-
amide—was synthesized as described (9). In cell-free PARP
assay, using NAD and purified PARP-1 enzyme, PJ34
inhibited PARP activity in a dose-dependent manner, with
an EC50 of 20 nM. The EC50 of the prototypical PARP
inhibitor 3-aminobenzamide was 200 M. Peroxynitrite-
and hydrogen perox ide- induced ox idat ion of
dihydrorhodamine-123 were unaffected by PJ34 in the
concentration range of 1 M to 10 mM, indicating that the
compound does not act as an antioxidant. The details of the
synthesis and pharmacologic characterization of PJ34 were
published previously (9).
Statistical analysis. All the data are represented as means
and 95% confidence intervals. Data of hemodynamic mea-
surements, infarct size, weight of different cavities, and lung
were analyzed with one-way analysis of variance, followed
by Student-Newman-Keuls (SNK) multiple comparisons
post-hoc analysis. Hemodynamic variables represented, for
each animal, the average of four values taken over a 10-min
period following stabilization. For the vascular rings studies,
dose-response curves were analyzed with analysis of variance
for repeated measurements, using a model including the
groups as between-subjects factor and concentrations as
within-subjects factor. When the F value was significant at
the 5% level, the different groups were compared at each
concentration level of acetylcholine, sodium nitroprusside,
or epinephrine using SNK multiple comparisons post-hoc
analysis and Student t test. Probability values of p  0.05
were considered significant. For vascular ring studies in
most of the animals we used two aortic rings from one rat to
avoid the potential error arising from regional heterogeneity
of vascular responses. However, only one mean response
from each animal was used for final calculation. For all the
other measurements we also used only one observation per rat.
RESULTS
Mortality. All the sham animals survived the 10 weeks of
the study. Among the 81 rats exposed to permanent ligation
of the LAD, 50 animals died during the first 24 h (sudden
death attributed to ventricular fibrillation) before the initi-
ation of therapy. In the 31 remaining animals, 3 PJ34-
treated and 2 saline-treated rats died during the 10 weeks of
observation. At the end of the observation period, the
number of surviving animals was thus 13 rats in the PJ34
group and 13 rats in the control groups. All sham animals
survived.
Cardiac function. EFFECT OF PJ34 ON THE CARDIAC DYS-
FUNCTION. Chronic heart failure was characterized by sig-
nificantly increased LVEDP and decreased LVSP, mean
blood pressure, dP/dt and dP/dt (Fig. 2). The PJ34
significantly attenuated the CHF-induced suppression of
systolic dP/dt and diastolic dP/dt and an increase in
LVEDP (Fig. 2). The PJ34 significantly improved de-
creased mean blood pressure in CHF and also tended to
increase LVSP (Fig. 2). The PARP inhibitor exerted no
significant effects on hemodynamic parameters in sham rats
(Fig. 2). The heart rates were not significantly different in all
groups studied (Fig. 2).
INFARCT SIZE AND CARDIAC REMODELING. The infarct
size in two groups was 28  5% (CHF) and 29  4%
(CHF  PJ34), respectively. We cannot rule out the
possibility that the method we used to determine the infarct
size led to an underestimation of the actual size of the
infarct, especially when considering the high mortality rate
of our model, reflecting extensive infarction in the dying
animals as well as the marked ventricular dysfunction noted
in the surviving animals.
Chronic heart failure induced a significant increase in the
weights of the LV and left and right atria (Fig. 3). The right
ventricular weight also tended to increase. Chronic heart
failure was also characterized by increased lung weights,
indicative of marked pulmonary edema secondary to cardiac
decompensation (Fig. 3). Treatment with PJ34 significantly
reduced the CHF-induced increase in LV, left and right
atrial, and lung weights (Fig. 3).
EVIDENCE FOR INCREASED NT FORMATION AND PARP AC-
TIVATION IN CHF IN THE HEARTS IN VIVO. Figure 4 shows
widespread increased cardiac NT formation in failing ven-
tricles and intramural vasculature (Fig. 4b), which was not
affected by PARP inhibitor treatment (Fig. 4c). The average
image NT staining intensity was 14  4 a.u. (n  4) in
sham animals, which was significantly (p  0.01; n  5)
increased by 80% and 64% to 25  3 a.u. and 23 
3 a.u. in the CHF and CHF  PJ34 groups, respectively.
As shown in Figure 5, a marked degree of PARP
activation was observed in the hearts isolated from rats with
CHF (Fig. 5b). The staining was mainly localized in the
nuclei of cardiac myocytes and endothelial cells. The PARP
activation was attenuated by treatment with PJ34 (Fig. 5c).
The percentage of PARP-positive nuclei of myocytes was
16  3 (n  6) in sham animals. Chronic heart failure
increased the fraction of PARP-positive nuclei to 42  5
(p  0.01; n  8). Treatment with PJ34 (for 10 weeks)
markedly decreased the percentage of PARP-positive nuclei
to 23  2 (p  0.01; n  6) in rats with CHF.
PARP INHIBITION IMPROVES CHF-INDUCED ENDOTHELIAL
DYSFUNCTION IN RATS. In agreement with previous reports
(23–25), ex vivo experiments demonstrated the loss of
endothelial function in rats with CHF (Fig. 6). Inhibition of
PARP restored normal vascular function in rats with CHF
(Fig. 6). Contractile and endothelium-independent relaxant
responses to sodium nitroprusside were unchanged (Fig. 6).
DISCUSSION
A multitude of new pharmacologic approaches have been
introduced during the past decade for experimental therapy
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of CHF. Although many of these approaches have been
successful in animal models and clinical trials, morbidity and
mortality from CHF remain high, and research into patho-
mechanisms of disease and new disease-modifying pharma-
cologic targets continues.
The present study demonstrates that CHF induced by
chronic ligation of the LAD in rats was associated with a
marked depression of LV function, impaired relaxation of
aortic rings to acetylcholine, and decreased blood pressure
without change in the heart rate. These results are consis-
tent with earlier reports using similar rat models (14,26,27).
The reduction in blood pressure is most likely related to
reduction in cardiac output while systemic resistance is
generally increased or unchanged (28). The results pre-
sented here document for the first time that in an experi-
mental model of CHF, the impaired cardiac and vascular
function is associated with an activation of PARP in the
myocardium and vasculature. Furthermore, we now show
that the cardiac and endothelial dysfunction is improved by
pharmacologic inhibition of PARP. Because we did not
measure cardiac output and calculate systemic vascular
resistance, we cannot completely rule out the possibility that
some of the beneficial effects of PJ34 on heart function were
related to its favorable influence on the peripheral circula-
tion. However, on the basis of the results of previous
investigations and our data presented in the current study, it
appears that PJ34 improved cardiac function by direct
influence on the heart itself. Indeed, in several studies
performed in isolated working hearts exposed to ischemia
and reperfusion, it has been shown that suppression of
PARP activity, either by pharmacologic (2,29,30) or by
genetic deletion of the PARP gene (31), produced a
significant improvement of cardiac function. In a study by
Pieper et al., PARP activation was directly demonstrated in
isolated hearts from wild-type mice following ischemia and
reperfusion (32). In contrast, PARP activation was not
detectable in hearts from PARP-deficient animals, and the
lack of PARP was associated with significant improvement
of cardiac contractility. These observations support a) that
PARP activation produces direct detrimental influence on
Figure 2. Improvement of cardiac dysfunction by pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase 10 weeks after permanent
ligation of left anterior descending coronary artery in a rat model of chronic heart failure (CHF). Effect of CHF and PJ34 on left ventricular systolic pressure
(LVSP), left ventricular end-diastolic pressure (LVEDP), left ventricular dP/dt, left ventricular dP/dt in rats. Results are mean  95% confidence
interval of 8 to 10 experiments in each group. *p  0.05 vs. S; #p  0.05 vs. CHF. BP  blood pressure; CHF  PJ34  chronic heart failure treated
with PJ34 (for 10 weeks); S  sham; S  PJ34  sham treated with PJ34 (for 10 weeks).
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cardiac function, and b) that PARP suppression can exert
direct benefit on cardiac function, independent from any
peripheral vascular effects.
Experimental and clinical studies have suggested an
increased production of reactive oxygen species (superoxide,
hydrogen peroxide, hydroxyl radical) in the failing myocar-
dium (12–17,25). The expression and activity of inducible
isoform of nitric oxide synthase (iNOS) is also increased in
the myocardium of patients with CHF (33,34). Impor-
tantly, a recent study has suggested correlation between
chronic overexpression of iNOS and peroxynitrite genera-
tion with cardiac enlargement, conduction defects, sudden
cardiac death and, less commonly, heart failure in mice (35).
Myocardial iNOS is also activated in rats with volume-
overload HF, and increased iNOS activity contributes to
depressed myocardial contractility and beta-adrenergic hy-
poresponsiveness (36). The combination of NO and super-
oxide yields peroxynitrite (37), which is able to trigger DNA
single-strand breakage and activation of PARP (1,5). Per-
oxynitrite generation has been demonstrated in various
models of CHF, and this species has been shown to impair
cardiac function via multiple mechanisms (15,38). In the
current study, similarly to that of Mihn et al. (15), we also
demonstrate widespread increased NT formation in failing
ventricles. Importantly, the increased NT formation in
CHF is not reduced by PARP inhibitor treatment, which is
consistent with our proposed scheme, where PARP activa-
tion lies downstream from the generation of oxidants.
A recently characterized mechanism of myocardial dys-
function involves the activation of the nuclear enzyme
PARP by DNA single-strand breaks generated in response
to increased oxidative and nitrosative stress. Evidence for
the importance of this pathway has been demonstrated in
hearts subjected to regional or global ischemia and reperfu-
sion (2,3,18–21,29–32). The mode of PARP inhibitors’
cardioprotective action involves a conservation of myocar-
dial energetics, as well as a prevention of the upregulation of
various proinflammatory pathways (cytokines, adhesion re-
ceptors, mononuclear cell infiltration) triggered by ischemia
and reperfusion (3,21,29). Similar to acute myocardial
Figure 3. Effect of pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase on cardiac remodeling and lung weight in rat model of
chronic heart failure (CHF) induced by permanent ligation of left anterior descending (LAD) coronary artery. Left ventricular (LVW), right ventricular
(RVW), left atrial (LAW), right atrial (RAW), and lung (LungW) weights in sham (S), PJ34-treated (for 10 weeks) sham (S  PJ34), CHF and
PJ34-treated (for 10 weeks) CHF (CHF  PJ34) rats. Results are mean  95% confidence interval of 8 to 10 experiments in each group. The weight of
each cavity and lung was normalized to the length of the right tibia. *p  0.05 vs. S; #p  0.05 vs. CHF.
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ischemia and reperfusion, both oxidant-mediated myocar-
dial injury and upregulation of various proinflammatory
processes play important roles in CHF. It is conceivable that
PARP inhibition exerts beneficial effects in the current
model by affecting both pathways of injury, and also by
suppressing positive feedback cycles they initiate.
We previously showed that massive PARP activation
contributes to necrotic cell death in the region of acute
myocardial infarct in rats and pigs (18,20). In the current
study we have delayed the start of PARP inhibitors’ admin-
istration to 24 h to prevent an effect on the primary process
of infarction, and to focus on the delayed pathophysiologic
processes in the noninfarcted myocardial tissue.
Chronic heart failure is characterized by impaired NO-
mediated vasodilation (39–41), which may contribute to
increased peripheral vascular resistance. The pathogenesis of
endothelial dysfunction associated with CHF appears to
involve enhanced oxidative stress from various local sources
(27,41), including iNOS, which in CHF paradoxically
appears to produce superoxide rather than NO (42). Reac-
tive oxidant species, including the cytotoxic oxidant per-
oxynitrite, are generated in various forms of vascular injury
(including circulatory shock, diabetes, and reperfusion inju-
ry), and are responsible for the impairment of endothelium-
dependent relaxations, in part via activation of PARP in the
endothelium (5,9–11). Importantly, a recent report has
demonstrated marked decreased NO availability and en-
hanced superoxide and peroxynitrite production in vascula-
ture of normotensive and hypertensive rats with CHF
induced by occlusion of the left coronary artery (43).
Figure 4. Evidence for increased nitrotyrosine (NT) formation in hearts from rats with chronic heart failure (CHF). Immunohistochemical staining for NT,
an indicator of peroxynitrite formation, in sham (a), CHF (b), and PJ34-treated CHF (c) rat hearts. Panel b shows widespread NT formation in myocytes
and intramural vasculature in rats with CHF. Treatment with PJ34 for 10 weeks (c) did not reduce NT formation in rat hearts with CHF. Similar
immunohistochemical profiles were seen in n  4 to 5 hearts per group.
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Consistent with these results, we also found increased NT
formation in intramural vasculature (Fig. 4) in failing
ventricles.
Our results obtained with PJ34 clearly demonstrate that
the impairment of the cardiac and endothelial function in
CHF—at least in the current experimental model—are
dependent on PARP activity. We propose that following
the myocardial infarction, the compensatory increased sym-
pathetic activity, the activated renin-angiotensin system,
and the increased workload of the noninfarcted regions lead
to myocardial hypertrophy, myocardial ischemia/functional
hypoxia, increased oxidative and nitrosative stress, and
PARP activation, which in turn results in rapid depletion of
the intracellular NAD and ATP pools, leading to cardiac
and vascular dysfunction. It is conceivable that the endo-
thelial PARP pathway and the cardiomyopathy in CHF are
interrelated: an impairment of the endothelial function may
lead to global or regional myocardial ischemia, which may
secondarily impair cardiac performance.
As with any compound, we cannot fully exclude the
possibility that PJ34 may also act at yet undetermined
pharmacologic sites other than PARP in the heart. How-
ever, PJ34 is one of the most potent, selective, and effective
bioavailable PARP inhibitors discovered to date (9), and in
contrast to some other pharmacologic inhibitors of PARP
(such as nicotinamide and 3-AB), it lacks antioxidant effects
(9) (Fig. 5). We have previously shown that the dose
regimen of PJ34 used in the current study effectively inhibits
Figure 5. Evidence for poly(adenosine diphosphate-ribose) polymerase (PARP) activation in hearts from rats with chronic heart failure (HF).
Immunohistochemical staining for poly(ADP-ribose) formation, an indicator of PARP activation, in sham (a), CHF (b), and PJ34-treated CHF (c) rat
hearts. Panel b shows poly(ADP-ribose) formation localized in the nuclei of myocytes and endothelial cells in rats with CHF. Treatment with PJ34 for
10 weeks (c) markedly reduced PARP activation in rats hearts with CHF. Similar immunohistochemical profiles were seen in six to eight hearts per group.
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PARP activation in the myocardium (4,11,20) under vari-
ous pathophysiologic conditions, and the current study also
confirmed this finding. Because of the similar protection
seen with PARP-deficient animals and PJ34 in various
animal models of cardiovascular disorders and immunohis-
tochemical results included in the current and other studies,
it is probable that PJ34 works via selective inhibition of
PARP activity (2,4,9–11,20,31,32). This is also supported
by our recent results demonstrating that in a mouse model
of doxorubicin-induced acute heart failure, both genetic
deletion of PARP and pharmacologic inhibition with PJ34
were associated with better preservation of myocardial
performance (44).
In conclusion, our study provides evidence that the PARP
activation importantly contributes to the pathogenesis of
cardiovascular dysfunction in an experimental model of
Figure 6. Reversal of chronic heart failure (CHF)-induced endothelial dysfunction by pharmacologic inhibition of poly(ADP-ribose) polymerase (PARP)
in rats: epinephrine-induced contractions (middle), acetylcholine-induced endothelium-dependent relaxation (upper), and sodium nitroprusside
(SNP)-induced endothelium-independent relaxations (lower). Each point of the curve represents mean  95% confidence interval of 7 to 10 experiments
in vascular rings. *p  0.05 vs. S; #p  0.05 vs. CHF. S  sham.
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CHF. Inhibition of PARP may represent a novel approach
for the experimental therapy of CHF.
Reprint requests and correspondence: Dr. Csaba Szabo´, Inotek
Corporation, Suite 419E, 100 Cummings Center, Beverly, Mas-
sachusetts 01915. E-mail: szabocsaba@aol.com.
REFERENCES
1. Szabo´ C, editor. Cell Death: The Role of PARP. Boca Raton, FL:
CRC Press, 2000.
2. Thiemermann C, Bowes J, Myint FP, Vane JR. Inhibition of the
activity of poly (ADP ribose) synthetase reduces ischemia-reperfusion
injury in the heart and skeletal muscle. Proc Natl Acad Sci U S A
1997;94:679–83.
3. Zingarelli B, Salzman AL, Szabo´ C. Genetic disruption of poly(ADP-
ribose) synthetase inhibits the expression of P-selectin and intercellular
adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ
Res 1998;83:85–94.
4. Szabo´ G, Bahrle S, Stumpf N, et al. Poly(ADP-ribose) polymerase
inhibition reduces reperfusion injury after heart transplantation. Circ
Res 2002;90:100–6.
5. Szabo´ C, Cuzzocrea S, Zingarelli B, O’Connor M, Salzman AL.
Endothelial dysfunction in a rat model of endotoxic shock. Importance
of the activation of poly(ADP-ribose) synthetase by peroxynitrite.
J Clin Invest 1997;100:723–35.
6. Liaudet L, Soriano FG, Szabo´ E`, et al. Protection against hemorrhagic
shock in mice genetically deficient in poly(ADP-ribose) polymerase.
Proc Natl Acad Sci U S A 2000;97:10203–8.
7. Eliasson MJ, Sampei K, Mandir AS, et al. Poly(ADP-ribose) poly-
merase gene disruption renders mice resistant to cerebral ischemia. Nat
Med 1997;3:1089–95.
8. Burkart V, Wang ZQ, Radons J, et al. Mice lacking the poly(ADP-
ribose) polymerase gene are resistant to pancreatic beta-cell destruction
and diabetes development induced by streptozotocin. Nat Med 1999;
5:314–9.
9. Soriano FG, Vira´g L, Jagtap P, et al. Diabetic endothelial dysfunction:
the role of poly(ADP-ribose) polymerase activation. Nat Med 2001;
7:108–13.
10. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo´ C. Rapid reversal
of the diabetic endothelial dysfunction by pharmacological inhibition
of poly(ADP-ribose) polymerase. Circ Res 2001;89:684–91.
11. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo´ E`, Szabo´ C. The
role of poly(ADP-ribose) polymerase in the development of cardio-
vascular dysfunction in diabetes mellitus. Diabetes 2002;51:514–21.
12. Ide T, Tsutsui H, Kinugawa S, et al. Mitochondrial electron transport
complex I is a potential source of oxygen free radicals in the failing
myocardium. Circ Res 1999;85:357–63.
13. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol
decreases myocardial oxygen consumption and increases mechanical
efficiency in dogs with pacing-induced heart failure. Circ Res 1999;
85:437–45.
14. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G.
Endothelial dysfunction in chronic myocardial infarction despite
increased vascular endothelial nitric oxide synthase and soluble guan-
ylate cyclase expression: role of enhanced vascular superoxide produc-
tion. Circulation 1999;100:292–8.
15. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA.
Peroxynitrite induced nitration and inactivation of myofibrillar creat-
ine kinase in experimental heart failure. Cardiovasc Res 2001;49:798–
807.
16. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves
myocardial efficiency in patients with idiopathic dilated cardiomyop-
athy. Circulation 2001;104:2407–11.
17. Cesselli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated
cardiac cell death is a major determinant of ventricular dysfunction and
failure in dog dilated cardiomyopathy. Circ Res 2001;89:279–86.
18. Liaudet L, Szabo´ E`, Timashpolsky L, Virag L, Cziraki A, Szabo´ C.
Suppression of poly(ADP-ribose) polymerase activation by
3-aminobenzamide in a rat model of myocardial infarction: long-term
morphological and functional consequences. Br J Pharmacol 2001;133:
1424–30.
19. Liaudet L, Yang Z, Al-Affar EB, Szabo C. Myocardial ischemic
preconditioning in rodents is dependent on poly(ADP-ribose) syn-
thetase. Mol Med 2001;7:406–17.
20. Faro R, Toyoda Y, McCully JD, et al. Myocardial protection by PJ34,
a novel potent poly(ADP-ribose) synthetase inhibitor. Ann Thorac
Surg 2002;73:575–81.
21. Zingarelli B, Cuzzocrea S, Zsengeller Z, Salzman AL, Szabo´ C.
Protection against myocardial ischemia and reperfusion injury by
3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase.
Cardiovasc Res 1997;36:205–15.
22. Pacher P, Hajnoczky G. Propagation of the apoptotic signal by
mitochondrial waves. EMBO J 2001;20:4107–21.
23. Teerlink JR, Clozel M, Fischli W, Clozel JP. Temporal evolution of
endothelial dysfunction in a rat model of chronic heart failure. J Am
Coll Cardiol 1993;22:615–20.
24. Driss AB, Devaux C, Henrion D, et al. Hemodynamic stresses induce
endothelial dysfunction and remodeling of pulmonary artery in exper-
imental compensated heart failure. Circulation 2000;101:2764–70.
25. Indik JH, Goldman S, Gaballa MA. Oxidative stress contributes to
vascular endothelial dysfunction in heart failure. Am J Physiol 2001;
281:H1767–70.
26. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improve-
ment of left ventricular remodeling and function by hydroxymethyl-
glutaryl coenzyme a reductase inhibition with cerivastatin in rats with
heart failure after myocardial infarction. Circulation 2001;104:982–5.
27. Francis J, Weiss RM, Wei SG, Johnson AK, Felder RB. Progression
of heart failure after myocardial infarction in the rat. Am J Physiol
Regul Integr Comp Physiol 2001;281:1734–45.
28. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of
ghrelin in cachexia associated with chronic heart failure: relationships
between ghrelin and anabolic/catabolic factors. Circulation 2001;104:
2034–8.
29. Docherty JC, Kuzio B, Silvester JA, Bowes J, Thiemermann C. An
inhibitor of poly(ADP-ribose) synthetase activity reduces contractile
dysfunction and preserves high energy phosphate levels during reper-
fusion of the ischaemic rat heart. Br J Pharmacol 1999;127:1518–24.
30. Szabados E, Literati-Nagy P, Farkas B, Sumegi B. BGP-15, a
nicotinic amidoxime derivate protecting heart from ischemia reperfu-
sion injury through modulation of poly(ADP-ribose) polymerase.
Biochem Pharmacol 2000;59:937–45.
31. Grupp IL, Jackson TM, Hake P, Grupp G, Szabo´ C. Protection
against hypoxia-reoxygenation in the absence of poly(ADP-ribose)
synthetase in isolated working hearts. J Mol Cell Cardiol 1999;31:
297–303.
32. Pieper AA, Walles T, Wei G, et al. Myocardial postischemic injury is
reduced by poly(ADP-ribose) polymerase-1 gene disruption. Mol Med
2000;6:271–82.
33. Fukuchi M, Hussain SN, Giaid A. Heterogeneous expression and
activity of endothelial and inducible nitric oxide synthases in end-stage
human heart failure: their relation to lesion site and beta-adrenergic
receptor therapy. Circulation 1998;98:132–9.
34. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide
synthase (iNOS) in the human heart: expression and localization in
congestive heart failure. J Mol Cell Cardiol 1998;30:1215–23.
35. Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpression of
iNOS in mice results in peroxynitrite generation, heart block, and
sudden death. J Clin Invest 2002;109:735–43.
36. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of
myocardial inducible nitric oxide synthase in contractile dysfunction
and beta-adrenergic hyporesponsiveness in rats with experimental
volume-overload heart failure. Circulation 2002;105:236–43.
37. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxyni-
trite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424–37.
38. Ferdina´ndy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxyni-
trite is a major contributor to cytokine-induced myocardial contractile
failure. Circ Res 2000;87:241–7.
39. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic
congestive heart failure. Am J Cardiol 1992;69:1596–601.
40. Ramsey MW, Goodfellow J, Jones CJ, Luddington LA, Lewis MJ,
Henderson AH. Endothelial control of arterial distensibility is im-
paired in chronic heart failure. Circulation 1995;92:3212–9.
41. Bauersachs J, Fleming I, Fraccarollo D, Busse R, Ertl G. Prevention of
endothelial dysfunction in heart failure by vitamin E: attenuation of
1015JACC Vol. 40, No. 5, 2002 Pacher et al.
September 4, 2002:1006–16 PARP Inhibition and CHF
vascular superoxide anion formation and increase in soluble guanylyl
cyclase expression. Cardiovasc Res 2001;51:344–50.
42. Miller AA, Megson IL, Gray GA. Inducible nitric oxide synthase-
derived superoxide contributes to hyperreactivity in small mesenteric
arteries from a rat model of chronic heart failure. Br J Pharmacol
2000;131:29–36.
43. Wiemer G, Itter G, Malinski T, Linz W. Decreased nitric oxide
availability in normotensive and hypertensive rats with failing hearts
after myocardial infarction. Hypertension 2001;38:1367–71.
44. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose)
polymerase contributes to development of doxorubicin-induced heart
failure. JPET 2002;300:862–7.
1016 Pacher et al. JACC Vol. 40, No. 5, 2002
PARP Inhibition and CHF September 4, 2002:1006–16
